Paul Matteis
Stock Analyst at Stifel
(2.96)
# 1,389
Out of 5,148 analysts
127
Total ratings
44.58%
Success rate
0.17%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Hold | $73 → $77 | $81.96 | -6.05% | 7 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $25 → $24 | $22.81 | +5.22% | 7 | Feb 26, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $445 → $466 | $486.03 | -4.12% | 21 | Feb 13, 2026 | |
| QURE uniQure | Maintains: Buy | $50 → $40 | $10.50 | +280.95% | 3 | Dec 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $183 → $188 | $132.38 | +42.02% | 11 | Dec 11, 2025 | |
| LBRX LB Pharmaceuticals | Maintains: Buy | $27 → $35 | $23.78 | +47.18% | 2 | Dec 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Buy | $36 → $39 | $16.15 | +141.49% | 5 | Dec 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $495 → $508 | $325.07 | +56.27% | 16 | Dec 11, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $28 | $17.60 | +59.09% | 1 | Nov 21, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Hold | $2 → $3 | $3.20 | -6.25% | 3 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $73 → $61 | $59.74 | +2.11% | 11 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $144 → $202 | $188.05 | +7.42% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $6.53 | +83.77% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $94 | $94.94 | -0.99% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $33.92 | -5.66% | 1 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $32 | $16.01 | +99.88% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $7.02 | +56.70% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $2.21 | +81.00% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $20.63 | -51.53% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $20.74 | +189.30% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $30.25 | +19.01% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $28.37 | +23.37% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $15.34 | +89.05% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.13 | +180.50% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.60 | +1,912.41% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $16.06 | +99.25% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.30 | +718.18% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $13.85 | +362.09% | 1 | Feb 21, 2018 |
Ionis Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $73 → $77
Current: $81.96
Upside: -6.05%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Hold
Price Target: $25 → $24
Current: $22.81
Upside: +5.22%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Hold
Price Target: $445 → $466
Current: $486.03
Upside: -4.12%
uniQure
Dec 11, 2025
Maintains: Buy
Price Target: $50 → $40
Current: $10.50
Upside: +280.95%
Neurocrine Biosciences
Dec 11, 2025
Maintains: Buy
Price Target: $183 → $188
Current: $132.38
Upside: +42.02%
LB Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $27 → $35
Current: $23.78
Upside: +47.18%
Dyne Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $16.15
Upside: +141.49%
Alnylam Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $495 → $508
Current: $325.07
Upside: +56.27%
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $28
Current: $17.60
Upside: +59.09%
Neumora Therapeutics
Nov 17, 2025
Maintains: Hold
Price Target: $2 → $3
Current: $3.20
Upside: -6.25%
Nov 6, 2025
Downgrades: Hold
Price Target: $73 → $61
Current: $59.74
Upside: +2.11%
Nov 6, 2025
Upgrades: Buy
Price Target: $144 → $202
Current: $188.05
Upside: +7.42%
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $6.53
Upside: +83.77%
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $94.94
Upside: -0.99%
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $33.92
Upside: -5.66%
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $16.01
Upside: +99.88%
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $7.02
Upside: +56.70%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $2.21
Upside: +81.00%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $20.63
Upside: -51.53%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $20.74
Upside: +189.30%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $30.25
Upside: +19.01%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $28.37
Upside: +23.37%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $15.34
Upside: +89.05%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $7.13
Upside: +180.50%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $0.60
Upside: +1,912.41%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $16.06
Upside: +99.25%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $3.30
Upside: +718.18%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $13.85
Upside: +362.09%